多がんスクリーニング市場：製品タイプ、検査タイプ、技術、がんタイプ、エンドユーザー別-2025-2030年の世界予測

多がんスクリーニング市場は、2023年に14億米ドルと評価され、2024年には15億3,000万米ドルに達すると予測され、CAGR 9.90％で成長し、2030年には27億2,000万米ドルになると予測されています。

多がんスクリーニングは、がんの早期発見における革新的な変化を表しており、症状が現れる前に1回の検査で複数のがん種を特定することを目指しています。がん罹患率と死亡率の上昇により、このアプローチはますます必要性を増しており、生存率を向上させるためには早期発見が不可欠であることを強調しています。多がんスクリーニングは、主に臨床現場や日常的な健康診断で応用され、がんの家族歴や遺伝的素因を持つような高リスク集団の早期発見を促進すると予測されます。最終用途の範囲には主に病院、診断研究所、がん研究センターが含まれます。市場成長の原動力となっているのは、ゲノムおよびバイオインフォマティクスの技術的進歩であり、がんバイオマーカーのより正確かつ包括的な検出を可能にしています。データ分析におけるAIの統合も、多がんスクリーニング機能の拡大に寄与しています。さらに、一般市民の意識の高まりと個別化医療の採用が潜在的な機会を生み出しています。しかし、高コスト、規制上のハードル、検査の感度と特異性に関する問題などの課題は、市場の成長を阻害する可能性があります。遺伝子情報に関する倫理的配慮やデータプライバシーに関する懸念は、さらに複雑さを増しています。これらの制約を克服するためには、技術革新によるコスト削減と検査精度の向上に焦点を当てた調査が必要です。新規バイオマーカーの統合や、高度なリスク評価のためのAIの活用は、技術革新を大きく推進する可能性があります。より優れたデータ管理ツールや、機密性の高い遺伝子情報を扱うための安全なプラットフォームの調査も不可欠です。AIやビッグデータ解析を専門とするハイテク企業との提携により、検出アルゴリズムを改良し、患者の転帰を改善するチャンスもあります。全体として、多がんスクリーニング市場は、これらの課題を克服し、進化するヘルスケア需要に対応するために最先端技術の応用を最適化することを条件として、大きく成長する態勢を整えています。

市場力学：急速に進化する多がんスクリーニング市場の主要市場インサイトを公開

多がんスクリーニング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん疾患の有病率の増加と高齢化率の上昇
  • ヘルスケア施設における多がんスクリーニングを推進する複数の政府イニシアティブ
• 市場抑制要因
  • 多がんスクリーニングに関連する、時間のかかる処置と高コスト
• 市場機会
  • リキッドバイオプシーの潜在的活用と多がん検出（MCD）研究センターの増加
  • がん診断治療法開発のための研究開発活動の活発化
• 市場の課題
  • 十分な安全性と有効性データ、検査性能のばらつきに関する懸念

ポーターの5つの力：多がんスクリーニング市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：多がんスクリーニング市場における外部からの影響の把握

外部マクロ環境要因は、多がんスクリーニング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析多がんスクリーニング市場における競合情勢の把握

多がんスクリーニング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス多がんスクリーニング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、多がんスクリーニング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の増加と高齢化の進行
    • ヘルスケア施設における多がんスクリーニングを促進する政府の取り組み
  • 抑制要因
    • 時間のかかる手順と多がんスクリーニングに関連する高コスト
  • 機会
    • 液体生検の潜在的利用と多発がん検出（MCD）研究センターの増加
    • がん診断治療手順の開発に向けた研究開発活動の増加
  • 課題
    • 十分な安全性と有効性のデータとテストパフォーマンスのばらつきに関連する懸念
• 市場セグメンテーション分析
  • 製品：AIを活用したスクリーニングおよび診断技術の革新的なイノベーションによるがんの早期発見の改善
  • 検査の種類：早期がん検出と患者の転帰改善には、体外診断と研究室開発の検査が好まれます。
  • 技術：早期検出と精度の効率性からPCRが好まれる
  • がんの種類：多専門分野スクリーニングの進歩を通じて革新とアクセシビリティを重視
  • エンドユーザー：学術、診断、ヘルスケア分野にわたる複数のがんスクリーニングの優先事項に対処するためにイノベーションとケアを調和させる
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 多がんスクリーニング市場：製品別

• AIと機械学習ベースのプラットフォーム
• 血液検査
• 呼気分析検査
• 糞便検査
• 遺伝子パネル/検査パネル
• 画像検査
  • コンピュータ断層撮影
  • 磁気共鳴画像
  • 陽電子放出断層撮影
• 唾液および頬粘膜スワブ検査
• 組織検査
• 尿検査

第7章 多がんスクリーニング市場テストタイプ別

• 体外診断
• 研究室開発テスト

第8章 多がんスクリーニング市場：技術別

• 蛍光in-situハイブリダイゼーション
• 免疫組織化学
• 次世代シーケンシング
• ポリメラーゼ連鎖反応

第9章 多がんスクリーニング市場がんの種類別

• 脳・神経系
• 乳腺・婦人科
• 内分泌
• 胃腸
• 泌尿生殖器
• 造血悪性腫瘍
• 肺
• 肉腫
• 肌

第10章 多がんスクリーニング市場：エンドユーザー別

• 学術・調査機関
• 診断および臨床検査室
• 病院

第11章 南北アメリカの多がんスクリーニング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の多がんスクリーニング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの多がんスクリーニング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 戦略的資金調達により、Freenomeの早期がん検出技術の進歩が促進される
  • PanGIA Biotechが液体生検プラットフォームで多発がん性疾患の検出を向上
  • Exact Sciences Corp.による遺伝性がんスクリーニング検査「Riskguard」のイントロダクション
  • SeekIn Inc.とOncolnvの戦略的提携により、世界のがん検出の取り組みを強化
  • AnchorDxとDiaCartaのコラボレーションにより、世界のがん検査に革命がもたらされる
  • バーニングロックバイオテック、OverCマルチガン検出血液検査で世界的評価を獲得
  • ElyptaがISO 13485：2016認証を取得し、GAGomeベースの多発がん検出を前進させる
  • Freenomeによる戦略的買収により、Oncimmune Ltdの高度な診断技術を通じてがん検査能力が強化される
  • ルーセンス、革新的なMCED血液検査でがん検出を向上：米国で戦略的発表

企業一覧

• ANPAC Bio-Medical Science Co., Ltd.
• Burning Rock Biotech Limited
• Caris Life Sciences
• Coyne Medical Ltd.
• Delfi Diagnostics, Inc.
• Elypta AB
• EpiCypher, Inc.
• Epigenomics AG
• Exact Sciences Corporation
• Foundation Medicine, Inc.
• Freenome Holdings, Inc.
• Fulgent Genetics, Inc.
• Gene Solutions
• Grail, LLC by Illumina, Inc.
• Guangzhou AnchorDx Medical Co., Ltd.
• Guardant Health, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Lucence Health Inc.
• Micronoma, Inc.
• MiRXES Pte Ltd.
• Myriad Genetics, Inc.
• Natera, Inc.
• Naveris, Inc.
• NeoGenomics Laboratories
• OneTest
• Siemens Healthineers AG
• StageZero Life Sciences. Ltd.

LIST OF FIGURES

• FIGURE 1. MULTICANCER SCREENING MARKET RESEARCH PROCESS
• FIGURE 2. MULTICANCER SCREENING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 16. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 18. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 20. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 24. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD THOUSAND)
• TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
• TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AI AND MACHINE LEARNING-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREATH ANALYSIS TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FECAL TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANELS/TEST PANELS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SALIVA & BUCCAL SWAB TEST, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TISSUE TEST, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY URINE-BASED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IN-VITRO DIAGNOSTICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TESTS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BRAIN/NERVOUS SYSTEM, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST & GYNECOLOGIC, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ENDOCRINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENITOURINARY, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SKIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 43. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 44. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 45. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 46. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 50. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 51. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 52. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 53. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 54. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 55. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 56. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 57. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 58. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 59. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 60. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 61. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 62. CANADA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 63. CANADA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 64. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 65. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 66. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 67. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 68. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 69. MEXICO MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 70. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 71. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 72. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 73. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 74. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 75. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 76. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 77. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 78. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 79. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 80. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
• TABLE 81. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 82. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 83. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 84. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 85. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 86. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 87. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 88. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 89. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 90. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 91. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 92. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 93. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 94. CHINA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 95. CHINA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 96. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 97. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 98. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 99. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 100. INDIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 101. INDIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 102. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 103. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 104. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 105. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 106. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 107. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 108. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 109. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 110. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 111. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 112. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 113. JAPAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 114. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 115. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 116. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 117. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 118. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 119. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 120. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 121. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 122. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 123. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 124. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 125. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 126. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 127. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 128. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 129. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 130. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 131. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 132. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 133. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 134. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 135. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 136. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 137. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 138. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 139. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 140. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 141. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 142. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 143. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 144. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 145. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 146. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 147. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 148. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 149. THAILAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 150. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 151. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 152. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 153. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 154. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 155. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 156. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 157. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 158. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 159. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 167. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 168. DENMARK MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 169. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 170. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 171. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 172. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 173. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 174. EGYPT MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 175. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 176. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 177. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 178. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 179. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 180. FINLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 181. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 182. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 183. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 184. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 185. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 186. FRANCE MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 187. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 188. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 189. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 190. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 191. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 192. GERMANY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 193. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 194. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 195. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 196. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 197. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 198. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 199. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 200. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 201. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 202. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 203. ITALY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 204. ITALY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 205. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 206. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 207. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 208. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 209. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 210. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 211. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 212. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 213. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 214. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 215. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 216. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 217. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 218. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 219. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 220. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 221. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 222. NORWAY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 223. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 224. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 225. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 226. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 227. POLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 228. POLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 229. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 230. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 231. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 232. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 233. QATAR MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 234. QATAR MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 235. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 236. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 237. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 238. QATAR MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 239. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 240. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 241. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 242. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 243. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 244. RUSSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 245. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 246. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 247. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 248. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 249. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 250. SAUDI ARABIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 251. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 252. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 253. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 254. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 255. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 256. SOUTH AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 257. SPAIN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 258. SPAIN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 259. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 260. SPAIN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 261. SPAIN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 262. SPAIN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 263. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 264. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 265. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 266. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 267. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 268. SWEDEN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 269. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 270. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 271. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 272. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 273. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 274. SWITZERLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 275. TURKEY MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 276. TURKEY MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 277. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 278. TURKEY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 279. TURKEY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 280. TURKEY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 281. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 282. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 283. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 284. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 285. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 286. UNITED ARAB EMIRATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 287. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD THOUSAND)
• TABLE 288. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD THOUSAND)
• TABLE 289. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
• TABLE 290. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
• TABLE 291. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD THOUSAND)
• TABLE 292. UNITED KINGDOM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
• TABLE 293. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 294. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

The Multicancer Screening Market was valued at USD 1.40 billion in 2023, expected to reach USD 1.53 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 2.72 billion by 2030.

Multicancer screening represents an innovative shift in early cancer detection, aiming to identify multiple cancer types through a single test before symptoms appear. This approach has become increasingly necessary due to rising cancer incidence and mortality rates, underscoring the critical need for early detection to improve survival rates. Multicancer screening is projected to be applied primarily in clinical settings and routine health check-ups, enhancing early detection among high-risk populations, such as those with a family history of cancer or existing genetic predispositions. The end-use scope primarily includes hospitals, diagnostic laboratories, and cancer research centers. Market growth is fueled by technological advancements in genomics and bioinformatics, allowing for more accurate and comprehensive detection of cancer biomarkers. The integration of AI in data analysis also contributes to the expansion of multicancer screening capabilities. Additionally, increasing public awareness and the adoption of personalized medicine are generating potential opportunities. However, challenges such as high costs, regulatory hurdles, and issues related to the sensitivity and specificity of tests can impede market growth. Ethical considerations and data privacy concerns regarding genetic information further add complexity. To overcome these limitations, research should focus on reducing costs through technological innovation and enhancing test accuracy. The integration of novel biomarkers and leveraging AI for advanced risk assessment could significantly propel innovation. Researching better data management tools and secure platforms for handling sensitive genetic information is also vital. Opportunities lie in partnerships with tech firms specializing in AI and big data analytics to refine detection algorithms and improve patient outcomes. Overall, the multicancer screening market is poised for substantial growth, contingent upon overcoming these challenges and optimizing the application of cutting-edge technologies to meet evolving healthcare demands.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multicancer Screening Market

The Multicancer Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of cancer disease and rising aging population
  • Several government initiatives promoting multicancer screening in healthcare facilities
• Market Restraints
  • Time-consuming procedures coupled with high cost associated with multicancer screening
• Market Opportunities
  • Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
  • Rising R&D activities for the development of cancer diagnostics treatment procedures
• Market Challenges
  • Concerns associated with adequate safety and efficacy data and variability in test performance

Porter's Five Forces: A Strategic Tool for Navigating the Multicancer Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multicancer Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multicancer Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multicancer Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multicancer Screening Market

A detailed market share analysis in the Multicancer Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multicancer Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multicancer Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd..

Market Segmentation & Coverage

This research report categorizes the Multicancer Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across AI and Machine Learning-Based Platforms, Blood-Based Tests, Breath Analysis Tests, Fecal Tests, Gene Panels/Test Panels, Imaging Tests, Saliva & Buccal Swab Test, Tissue Test, and Urine-Based Tests. The Imaging Tests is further studied across Computed Tomography, Magnetic Resonance Imaging, and Positron Emission Tomography.
• Based on Test Type, market is studied across In-vitro diagnostics and Laboratory Developed Tests.
• Based on Technology, market is studied across Fluorescence In-Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing, and Polymerase Chain Reaction.
• Based on Cancer Type, market is studied across Brain/Nervous System, Breast & Gynecologic, Endocrine, Gastrointestinal, Genitourinary, Hematological Malignancies, Lung, Sarcoma, and Skin.
• Based on End User, market is studied across Academic & Research Institutions, Diagnostic & Clinical Laboratories, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
    • 5.1.1.2. Several government initiatives promoting multicancer screening in healthcare facilities
  • 5.1.2. Restraints
    • 5.1.2.1. Time-consuming procedures coupled with high cost associated with multicancer screening
  • 5.1.3. Opportunities
    • 5.1.3.1. Potential utilization of liquid biopsy and rising multicancer detection (MCD) research centers
    • 5.1.3.2. Rising R&D activities for the development of cancer diagnostics treatment procedures
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with adequate safety and efficacy data and variability in test performance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Improvement in early cancer detection through revolutionary innovations in ai-enhanced screening and diagnostic technologies
  • 5.2.2. Test Type: In-vitro diagnostics and laboratorydeveloped tests are preferred for early cancer detection and improve patient outcomes
  • 5.2.3. Technology: Significant preference toward PCR for its efficiency in early detection and accuracy
  • 5.2.4. Cancer Type: Emphasizing innovation and accessibility through advancement in the multispeciality screening
  • 5.2.5. End-User: Harmonizing innovation and care to navigate multi cancer screening priorities across academic, diagnostic, and healthcare sectors
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Multicancer Screening Market, by Product

• 6.1. Introduction
• 6.2. AI and Machine Learning-Based Platforms
• 6.3. Blood-Based Tests
• 6.4. Breath Analysis Tests
• 6.5. Fecal Tests
• 6.6. Gene Panels/Test Panels
• 6.7. Imaging Tests
  • 6.7.1. Computed Tomography
  • 6.7.2. Magnetic Resonance Imaging
  • 6.7.3. Positron Emission Tomography
• 6.8. Saliva & Buccal Swab Test
• 6.9. Tissue Test
• 6.10. Urine-Based Tests

7. Multicancer Screening Market, by Test Type

• 7.1. Introduction
• 7.2. In-vitro diagnostics
• 7.3. Laboratory Developed Tests

8. Multicancer Screening Market, by Technology

• 8.1. Introduction
• 8.2. Fluorescence In-Situ Hybridization
• 8.3. Immunohistochemistry
• 8.4. Next-Generation Sequencing
• 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Cancer Type

• 9.1. Introduction
• 9.2. Brain/Nervous System
• 9.3. Breast & Gynecologic
• 9.4. Endocrine
• 9.5. Gastrointestinal
• 9.6. Genitourinary
• 9.7. Hematological Malignancies
• 9.8. Lung
• 9.9. Sarcoma
• 9.10. Skin

10. Multicancer Screening Market, by End User

• 10.1. Introduction
• 10.2. Academic & Research Institutions
• 10.3. Diagnostic & Clinical Laboratories
• 10.4. Hospitals

11. Americas Multicancer Screening Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Multicancer Screening Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Multicancer Screening Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Strategic Funding Fuels Freenome's Advancement in Early Cancer Detection Technology
  • 14.3.2. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
  • 14.3.3. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
  • 14.3.4. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
  • 14.3.5. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
  • 14.3.6. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
  • 14.3.7. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
  • 14.3.8. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
  • 14.3.9. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.

Companies Mentioned

• 1. ANPAC Bio-Medical Science Co., Ltd.
• 2. Burning Rock Biotech Limited
• 3. Caris Life Sciences
• 4. Coyne Medical Ltd.
• 5. Delfi Diagnostics, Inc.
• 6. Elypta AB
• 7. EpiCypher, Inc.
• 8. Epigenomics AG
• 9. Exact Sciences Corporation
• 10. Foundation Medicine, Inc.
• 11. Freenome Holdings, Inc.
• 12. Fulgent Genetics, Inc.
• 13. Gene Solutions
• 14. Grail, LLC by Illumina, Inc.
• 15. Guangzhou AnchorDx Medical Co., Ltd.
• 16. Guardant Health, Inc.
• 17. Invitae Corporation
• 18. Laboratory Corporation of America Holdings
• 19. Lucence Health Inc.
• 20. Micronoma, Inc.
• 21. MiRXES Pte Ltd.
• 22. Myriad Genetics, Inc.
• 23. Natera, Inc.
• 24. Naveris, Inc.
• 25. NeoGenomics Laboratories
• 26. OneTest
• 27. Siemens Healthineers AG
• 28. StageZero Life Sciences. Ltd.